Season 14 · Episode 11
S14 Ep11: Breaking Down the Rationale for Targeting TROP2 in TNBC
OncLive® On Air · OncLive® On Air
September 12, 202514m 48s
Audio is streamed directly from the publisher (audioboom.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this podcast, experts Filipa Lynce, MD, and Rita Nanda, MD, discuss unmet needs in triple-negative breast cancer (TNBC) and the rationale for using TROP2-targeting antibody-drug conjugates (ADCs) in this disease.